Published on
March 21, 2022

Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study

The Company’s Wholly Owned Contract Research Organization has Been  Engaged by Lophos Pharmaceuticals to Evaluate a Path to Market for  Sustainably Grown, Peyote-Derived Natural Health Products 

Vancouver, British Columbia, March 21, 2022 / Globe Newswire / – Wellbeing Digital Sciences Inc.  (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based  healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital  therapeutics and contract research, is pleased to announce that its wholly owned subsidiary, KGK Science  Inc. (“KGK”) has been engaged by Lophos Pharmaceuticals Inc. (“Lophos”) to evaluate a path to market  for sustainably grown, peyote-derived natural health products (“NHPs”). Lophos is a Canadian psychedelic  research company focused on cultivation and drug development.  

Peyote has legal status in Canada, but mescaline – the drug derived from the plant– remains a Schedule 3  controlled substance. With a focus on NHPs, potential paths to market will be evaluated based on the safety  and sanitary requirements, quality specifications for peyote-derived inputs, and permissible label claims for  packaging and sales.  

Management Commentary  

“Lophos is currently exploring the potential benefits of a peyote-derived natural health product with the  support of KGK Science. There are challenges to growing peyote, and the thirteen-year-long natural  regrowth cycle is a major threat to the endangered plant. At Lophos, we are researching accelerated,  responsible cultivation techniques for reducing the long growth cycle. The goal is to provide our partners  with therapeutic peyote derivatives, grown in a sustainable manner that are beneficial to the plant itself, and  respectful integrations of traditional medicinal plants,” said Claire Stawnyczy, Founder and CEO of  Lophos.  

“We are very excited to engage with Lophos. Peyote and mescaline in general are currently  underrepresented in the psychedelic medicine sector, given their traditional medicinal uses. Lophos  provides a critically important sustainable supply of cacti to the market. We plan to utilize our expertise in  natural health products to aid Lophos in bringing to market, innovative and safe products for the Canadian  consumer,” added Najla Guthrie, President and CEO of KGK.


Lophos Pharmaceuticals Inc. is a biosciences company that specializes in Peyote research, cultivation,  preservation, and drug development. We develop novel therapies and natural health treatments that aim to  restore and improve the quality of life for patients. Through advanced cultivation and harvesting techniques,  Lophos will provide our partners with medical grade inputs and our patients with access to safe and effective  mescaline-based therapeutics.  

For more information please contact:  

Alex Krause - Cushion Communications Inc. 


Founded in 1997, KGK is a leading North American contract research organization based in London,  Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical,  cannabis and emerging psychedelic industries. The business has successfully helped hundreds of companies  with custom designed clinical trials and claim substantiation strategies to move products into global  markets. KGK’s other existing service lines include expert regulatory support and compliance solutions,  participant recruitment, research support services and consulting services. On an approximate basis, the  business to date has produced 150 publications, executed over 400 clinical trials across more than 40  indications, amassed 25,000 participants in its database and collected 10 million data points.  


Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare  company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and  contract research. Its mission is supported by a network of North American clinics that provide ketamine assisted therapies and other types of treatment to patients as well as through a contract research organization  that offers clinical trials services to clients pursuing drug development. In essence, the company exists to  make breakthrough treatments more accessible and to offer patients transformational experiences.  

On behalf of:  


"Adam Deffett"  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  



Twitter: @Wellbeing_IR  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding  the Company’s business, assets or investments, as well other statements that are not historical facts. Readers 

are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that  the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking  statements involve numerous assumptions, known and unknown risks and uncertainties, both general and  specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to  differ materially from any estimates or projections of future performance or results expressed or implied by  such forward-looking statements. These assumptions, risks and uncertainties include, among other things,  the state of the economy in general and capital markets in particular, investor interest in the business and  prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release.  Except as required by law, the Company disclaims any intention and assumes no obligation to update or  revise any forward-looking statements, whether as a result of new information, future events or otherwise,  except as required by applicable securities law. Additionally, the Company undertakes no obligation to  comment on the expectations of, or statements made, by third parties in respect of the matters discussed  above.